Dose tapering and early discontinuation to increase cost-effectiveness of immunotherapy trial number 1
Phase 3
Recruiting
- Conditions
- Lung cancer10038666
- Registration Number
- NL-OMON54321
- Lead Sponsor
- Radboud Universitair Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 750
Inclusion Criteria
Eligible for treatment of non-small cell lung cancer with pembrolizumab in line
with the current ESMO treatment guidelines
Exclusion Criteria
Not willing to give informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>1-year survival</p><br>
- Secondary Outcome Measures
Name Time Method <p>Biomarker performance to predict treatment response</p><br>